SG Americas Securities LLC Cuts Stock Holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX)

SG Americas Securities LLC reduced its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 6.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,637 shares of the company's stock after selling 2,833 shares during the quarter. SG Americas Securities LLC's holdings in BioNTech were worth $3,518,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Van ECK Associates Corp boosted its position in BioNTech by 25.1% in the fourth quarter. Van ECK Associates Corp now owns 118,418 shares of the company's stock worth $13,493,000 after purchasing an additional 23,733 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of BioNTech during the 4th quarter worth $1,118,000. Vontobel Holding Ltd. boosted its holdings in shares of BioNTech by 24.6% in the 4th quarter. Vontobel Holding Ltd. now owns 21,385 shares of the company's stock worth $2,437,000 after buying an additional 4,227 shares during the last quarter. AlphaCentric Advisors LLC bought a new position in BioNTech during the fourth quarter valued at about $168,000. Finally, Flossbach Von Storch SE grew its position in BioNTech by 1.1% during the fourth quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company's stock valued at $502,160,000 after buying an additional 47,236 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Stock Down 1.3%

BNTX traded down $1.36 during trading on Tuesday, hitting $104.97. The stock had a trading volume of 765,167 shares, compared to its average volume of 950,009. The stock has a 50 day simple moving average of $101.59 and a two-hundred day simple moving average of $107.87. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18. BioNTech SE Sponsored ADR has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a market capitalization of $25.23 billion, a PE ratio of -30.87 and a beta of 1.29.

Wall Street Analyst Weigh In

BNTX has been the topic of several research analyst reports. JPMorgan Chase & Co. dropped their price objective on BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. Leerink Partners set a $112.00 price target on BioNTech in a research report on Monday, June 2nd. Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. The Goldman Sachs Group started coverage on BioNTech in a report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price objective for the company. Finally, Citigroup reaffirmed a "buy" rating and set a $140.00 price objective (down from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $137.86.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.